^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma

Published date:
02/16/2022
Excerpt:
...we evaluated the efficacy of sapanisertib in patients with treatment-refractory metastatic renal cell carcinoma...Diminished or loss of PTEN expression by immunohistochemistry was seen in 8 of 21 patients and trended toward shorter PFS compared with intact PTEN (median 1.9 v 3.7 months; hazard ratio 2.5; 95% CI, 0.9 to 6.7; P = .055)....Sapanisertib had minimal activity in treatment-refractory mRCC independent of mTOR pathway alterations.
DOI:
10.1200/PO.21.00448
Trial ID: